Literature DB >> 25670033

A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer.

Shane Stegeman1, Leire Moya1, Luke A Selth2, Amanda B Spurdle1, Judith A Clements1, Jyotsna Batra3.   

Abstract

The oncogene MDM4, also known as MDMX or HDMX, contributes to cancer susceptibility and progression through its capacity to negatively regulate a range of genes with tumour-suppressive functions. As part of a recent genome-wide association study it was determined that the A-allele of the rs4245739 SNP (A>C), located in the 3'-UTR of MDM4, is associated with an increased risk of prostate cancer. Computational predictions revealed that the rs4245739 SNP is located within a predicted binding site for three microRNAs (miRNAs): miR-191-5p, miR-887 and miR-3669. Herein, we show using reporter gene assays and endogenous MDM4 expression analyses that miR-191-5p and miR-887 have a specific affinity for the rs4245739 SNP C-allele in prostate cancer. These miRNAs do not affect MDM4 mRNA levels, rather they inhibit its translation in C-allele-containing PC3 cells but not in LNCaP cells homozygous for the A-allele. By analysing gene expression datasets from patient cohorts, we found that MDM4 is associated with metastasis and prostate cancer progression and that targeting this gene with miR-191-5p or miR-887 decreases in PC3 cell viability. This study is the first, to our knowledge, to demonstrate regulation of the MDM4 rs4245739 SNP C-allele by two miRNAs in prostate cancer, and thereby to identify a mechanism by which the MDM4 rs4245739 SNP A-allele may be associated with an increased risk for prostate cancer.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  MDM4; microRNA; prostate cancer; single nucleotide polymorphism

Mesh:

Substances:

Year:  2015        PMID: 25670033     DOI: 10.1530/ERC-15-0013

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  31 in total

1.  Association of KLK3, VAMP8 and MDM4 Genetic Variants within microRNA Binding Sites with Prostate Cancer: Evidence from Serbian Population.

Authors:  Nevena Kotarac; Zorana Dobrijevic; Suzana Matijasevic; Dusanka Savic-Pavicevic; Goran Brajuskovic
Journal:  Pathol Oncol Res       Date:  2020-06-17       Impact factor: 3.201

2.  Circulating miRNA 887 is differentially expressed in ARDS and modulates endothelial function.

Authors:  Andrew J Goodwin; Pengfei Li; Perry V Halushka; James A Cook; Aman S Sumal; Hongkuan Fan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-04-22       Impact factor: 5.464

3.  HIF-2α, acting via miR-191, is involved in angiogenesis and metastasis of arsenite-transformed HBE cells.

Authors:  Wenchao Xu; Fei Luo; Baofei Sun; Hua Ye; Jun Li; Le Shi; Yi Liu; Xiaolin Lu; Bairu Wang; Qingling Wang; Qizhan Liu; Aihua Zhang
Journal:  Toxicol Res (Camb)       Date:  2015-11-06       Impact factor: 3.524

Review 4.  Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.

Authors:  Nicholas H Farina; Areg Zingiryan; Michael A Vrolijk; Scott D Perrapato; Steven Ades; Gary S Stein; Jane B Lian; Christopher C Landry
Journal:  J Cell Physiol       Date:  2018-04-16       Impact factor: 6.384

Review 5.  MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Authors:  Jin Wu; Guanting Lu; Xinjiang Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 6.  Genetic Modifiers of the p53 Pathway.

Authors:  Subhasree Basu; Maureen E Murphy
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

7.  Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population.

Authors:  Mohammad Hashemi; Nazanin Moradi; Seyed Amir Mohsen Ziaee; Behzad Narouie; Mohammad Hosein Soltani; Maryam Rezaei; Ghazaleh Shahkar; Mohsen Taheri
Journal:  J Adv Res       Date:  2016-03-29       Impact factor: 10.479

8.  MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo.

Authors:  Qi-Guang Chen; Wei Zhou; Tao Han; Shu-Qi Du; Zhen-Hua Li; Zhe Zhang; Guang-Yi Shan; Chui-Ze Kong
Journal:  Tumour Biol       Date:  2015-09-07

Review 9.  Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.

Authors:  Dennis M Timmerman; Tessa L Remmers; Sanne Hillenius; Leendert H J Looijenga
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 10.  Role of Sex in the Therapeutic Targeting of p53 Circuitry.

Authors:  Francesca Mancini; Ludovica Giorgini; Emanuela Teveroni; Alfredo Pontecorvi; Fabiola Moretti
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.